Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma

NCT04609241 is registered in ClinicalTrials.gov with Zhejiang University as lead sponsor.

NCT NCT04609241
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04609241 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Trial for the Safety and Efficacy of Murine CD79b CAR-T Therapy for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia and B-cell Non-Hodgkin's Lymphoma
Lead sponsor
Zhejiang University
Phase
Phase 1
Overall status
Not yet recruiting
Start date
November 15, 2020
Completion date
November 15, 2026
Enrollment
72 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

relapsed and/or refractory acute lymphoblastic leukemia, relapsed and/or refractory b-cell non-hodgkin's lymphoma